Seres Therapeutics, Inc.

MCRBSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1609809

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	—	—	—	$11.9M	$27.2M
Research and Development Expense	$117.6M	$109.7M	$141.9M	$90.6M	$80.1M
Operating Expenses	$195.1M	$179.9M	$209.4M	$121.3M	$106.4M
Operating Income (Loss)	-$195.1M	-$179.9M	-$64.5M	-$88.1M	-$71.9M
Nonoperating Income (Expense)	$5.0M	-$3.7M	-$1.1M	-$997.0K	$1.6M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$113.7M	-$250.2M	-$65.6M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$139.8M	$358.6M	$348.8M	$354.9M	$342.9M
Assets, Current	$38.7M	$175.4M	$194.8M	$303.6M	$268.8M
Cash and Cash Equivalents, at Carrying Value	$30.8M	$128.0M	$163.0M	$180.0M	$116.0M
Accounts Receivable, after Allowance for Credit Loss, Current	$0.00	—	—	—	$9.4M
Inventory, Net	—	—	$0.00	—	—
Liabilities	$126.0M	$403.5M	$338.0M	$223.4M	$168.2M
Liabilities, Current	$41.2M	$98.7M	$85.6M	$82.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$117.4M	-$228.8M	$6.7M	-$93.6M	-$76.5M
Net Cash Provided by (Used in) Investing Activities	$10.6M	$82.4M	$64.1M	-$158.9M	-$30.5M
Net Cash Provided by (Used in) Financing Activities	$71.7M	$129.6M	$1.2M	$303.4M	$86.2M
Payments to Acquire Property, Plant, and Equipment	$8.0M	$9.8M	$9.6M	$591.0K	$1.0M
Payments for Repurchase of Common Stock	—	—	—	—	—

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)